Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add filters








Year range
1.
Rev. Soc. Bras. Clín. Méd ; 14(3): 163-165, jul. 2016. Ilus
Article in Portuguese | LILACS | ID: biblio-2130

ABSTRACT

A doença de Castleman é um distúrbio linfoproliferativo raro. Há três tipos histológicos: hialino-vascular (mais comum), variante de células plasmáticas e forma mista. A forma hialino-vascular é caracterizada tipicamente por apresentar uma evolução clínica benigna e localizada, sem sintomas constitucionais. É geralmente tratada com cirurgia e/ou radioterapia. A doença multicêntrica apresenta sintomas sistêmicos. Ainda não há um consenso sobre qual a melhor abordagem terapêutica. Reportamos o caso da doença em um homem de 47 anos com diagnóstico de doença de Castleman variante hialino-vascular e anemia hemolítica autoimune associada, com presença de CD-20, CD-10, CD3 e Ki67 positivos. Foi tratado com protocolo quimioterápico esquema CHOP e corticoterapia com prednisona, evoluindo com melhora do quadro.


Castleman's disease is a rare lymphoproliferative disorder. There are three histological types: hyaline-vascular (most common), plasma cell variant, and mixed form. The hyaline-vascular form is typically characterized by a benign and localized clinical course without constitutional symptoms. It is usually treated with surgery and/or radiotherapy. The multicentric disease has systemic symptoms. There is still no consensus on the best therapy approach. We report a case of the disease in a 47-year-old man diagnosed with hyaline-vascular variant of Castleman's disease, and associated Autoimmune Hemolytic Anemia, with the presence of CD20-positive, CD10-positive, CD3-positive and Ki67-positive cells. He was treated with chemotherapy protocol of CHOP regimen and corticotherapy with Prednisone, and evolved with improvement.


Subject(s)
Humans , Male , Middle Aged , Anemia, Hemolytic, Autoimmune/diagnosis , Castleman Disease/drug therapy , Diagnosis, Differential , Immunohistochemistry , Lymphoproliferative Disorders
SELECTION OF CITATIONS
SEARCH DETAIL